Peritonitis: Clinical Trials

9 trials for Peritonitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed. 9 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 9
Phase 22Completed 2

Follow Peritonitis: new trials by email Literature Review of Peritonitis trials Research Report on Peritonitis

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis
Meropenem 1000 mg, Aztreonam 2000 mg, automated peritoneal dialysis with following long time dwell - Peritoneal Dialysis Associated Peritonitis, Peritoneal Dialysis (PD)
Phase 2 / Phase 3CompletedKarl Landsteiner Insitute for Nephrology and Haemato-Oncology122021-08-312025-08-11
Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites
Rifaximin, Placebo - Cirrhosis, Ascites
Phase 3CompletedCentre Hospitalier Universitaire de Besancon1602018-06-052025-04-10
Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock
standard therapy, hemoperfusion - Peritonitis, Septic Shock
Phase 3CompletedMeditor SAS2432010-10-012013-12-18
Protective Effect of N-acetylcysteine Against From Ototoxicity
N-acetylcysteine - Hearing Loss, Extreme
Phase 2 / Phase 3CompletedTC Erciyes University602010-06-012011-11-16
SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection
duration of antibiotics - Peritonitis
Phase 3CompletedUniversity of Virginia5182008-09-012018-05-22
Treatment Duration for Abdominal Tuberculosis
RNTCP Category I treatment for 6 months, RNTCP Category I treatment for 9months - Tuberculosis
Phase 3CompletedAll India Institute of Medical Sciences1972008-07-012015-07-03
Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections
tigecycline - Abdominal Abscess
Phase 3CompletedWyeth is now a wholly owned subsidiary of Pfizer2002005-11-012009-07-07
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
doripenem - Bacterial Infections and Mycoses, Appendicitis
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.4832004-03-012011-06-10
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Doripenem - Bacterial Infections and Mycoses, Appendicitis
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.4782004-03-012011-06-10

Narrower conditions

Appendicitis (2)  ·  Bacterial Infections and Mycoses (2)  ·  Cholecystitis (2)  ·  Pancreatitis (2)  ·  Abdominal Abscess (1)  ·  Ascites (1)  ·  Community-Acquired Infections (1)  ·  Cross Infection (1)  ·  Deafness (1)  ·  Fibrosis (1)  ·  Kidney Failure, Chronic (1)  ·  Ototoxicity (1)  ·  Peritonitis, Tuberculous (1)  ·  Sepsis (1)

Broader conditions

Digestive System Diseases (9)  ·  Infections (9)  ·  Intraabdominal Infections (9)  ·  Peritoneal Diseases (9)  ·  Pathologic Processes (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Biliary Tract Diseases (2)  ·  Cecal Diseases (2)  ·  Disease Attributes (2)  ·  Gallbladder Diseases (2)  ·  Gastroenteritis (2)  ·  Gastrointestinal Diseases (2)  ·  Inflammation (2)  ·  Intestinal Diseases (2)  ·  Pancreatic Diseases (2)

Interventions

Doripenem (2)  ·  Acetylcysteine (1)  ·  Aztreonam (1)  ·  Hemoperfusion (1)  ·  Meropenem (1)  ·  Rifaximin (1)  ·  Tigecycline (1)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)  ·  All India Institute of Medical Sciences (1)  ·  Centre Hospitalier Universitaire de Besancon (1)  ·  Karl Landsteiner Insitute for Nephrology and Haemato-Oncology (1)  ·  Meditor SAS (1)  ·  TC Erciyes University (1)  ·  University of Virginia (1)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (1)

Countries

France (2)  ·  Austria (1)  ·  Canada (1)  ·  China (1)  ·  India (1)  ·  Turkey (Türkiye) (1)  ·  United States (1)

Top investigators

Alexandra Heurgue-Berlot, MD (1)  ·  Alexandre Louvet, MD, PhD (1)  ·  Christophe Bureau, MD, PhD (1)  ·  Claire Francoz, MD (1)  ·  Didier Payen, MD (1)  ·  Dr Govind K Makharia, MD, DM, DNB (1)  ·  Edouard Bardou-Jacquet, MD (1)  ·  Eric Nguyen-Khac, MD, PhD (1)  ·  Fanny Lebosse, MD (1)  ·  Ghassan Riachi, MD (1)  ·  Isabelle Ollivier, MD (1)  ·  Isabelle Rosa-Hezode, MD (1)  ·  Ismail Kocyigit, MD (1)

Results publications

PMID 19670912, PMID 20211892, PMID 19036670, PMID 20663130, PMID 25073872, PMID 25862039, PMID 25969531, PMID 25992746, PMID 40653111

NIH funding

R01GM081510 (1)